Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Background Many patients receiving dialysis in the USA share the socioeconomic characteristics of underserved communities, and undergo routine monthly laboratory testing, facilitating a practical, unbiased, and repeatable assessment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence. Methods For this cross-sectional study, in partnership with a central laboratory that receives samples from approximately 1300 dialysis facilities across the USA, we tested the remainder plasma of 28 503 randomly selected adult patients receiving dialysis in July, 2020, using a spike protein receptor binding domain total antibody chemiluminescence assay (100% sensitivity, 99·8% specificity). We extracted data on age, sex, race and ethnicity, and residence and facility ZIP codes from the anonymised electronic health records, linking patient-level residence data with cumulative and daily cases and deaths per 100 000 population and with nasal swab test positivity rates. We standardised prevalence estimates according to the overall US dialysis and adult population, and present estimates for four prespecified strata (age, sex, region, and race and ethnicity). Findings The sampled population had similar age, sex, and race and ethnicity distribution to the US dialysis population, with a higher proportion of older people, men, and people living in majority Black and Hispanic neighbourhoods than in the US adult population. Seroprevalence of SARS-CoV-2 was 8·0% (95% CI 7·7–8·4) in the sample, 8·3% (8·0–8·6) when standardised to the US dialysis population, and 9·3% (8·8–9·9) when standardised to the US adult population. When standardised to the US dialysis population, seroprevalence ranged from 3·5% (3·1–3·9) in the west to 27·2% (25·9–28·5) in the northeast. Comparing seroprevalent and case counts per 100 000 population, we found that 9·2% (8·7–9·8) of seropositive patients were diagnosed. When compared with other measures of SARS-CoV-2 spread, seroprevalence correlated best with deaths per 100 000 population (Spearman's ρ=0·77). Residents of non-Hispanic Black and Hispanic neighbourhoods experienced higher odds of seropositivity (odds ratio 3·9 [95% CI 3·4–4·6] and 2·3 [1·9–2·6], respectively) compared with residents of predominantly non-Hispanic white neighbourhoods. Residents of neighbourhoods in the highest population density quintile experienced increased odds of seropositivity (10·3 [8·7–12·2]) compared with residents of the lowest density quintile. County mobility restrictions that reduced workplace visits by at least 5% in early March, 2020, were associated with lower odds of seropositivity in July, 2020 (0·4 [0·3–0·5]) when compared with a reduction of less than 5%. Interpretation During the first wave of the COVID-19 pandemic, fewer than 10% of the US adult population formed antibodies against SARS-CoV-2, and fewer than 10% of those with antibodies were diagnosed. Public health efforts to limit SARS-CoV-2 spread need to especially target racial and ethnic minority and densely populated communities. Funding Ascend Clinical Laboratories.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
US Renal Data System 2016 Annual Data Report: Epidemiology of Kidney Disease in the United States
Saran, R., Robinson, B., Abbott, K. C., Agodoa, L. Y. C., Albertus, P., Ayanian, J., Balkrishnan, R., Bragg-Gresham, J., Cao, J., Chen, J. L. T., et al. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.12.004 · Cited by 2,191
Self-citationCOVID-19 and African Americans
Yancy, C. W. (2020) · JAMA · doi:10.1001/jama.2020.6548 · Cited by 1,934
Pollán, M., Pérez-Gómez, B., Pastor-Barriuso, R., Oteo, J., Hernán, M. A., Pérez-Olmeda, M., Sanmartín, J. L., Fernández-García, A., Cruz, I., Fernández de Larrea, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31483-5 · Cited by 1,639
Grasselli, G., Greco, M., Zanella, A., Albano, G., Antonelli, M., Bellani, G., Bonanomi, E., Cabrini, L., Carlesso, E., Castelli, G., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.3539 · Cited by 1,612
Rao, J. N. K., & Scott, A. J. (1984) · The Annals of Statistics · doi:10.1214/aos/1176346391 · Cited by 1,280
Korn, E. L., & Graubard, B. I. (1999) · Wiley eBooks · doi:10.1002/9781118032619 · Cited by 1,044
Rao, J. N. K., & Scott, A. J. (1981) · Journal of the American Statistical Association · doi:10.1080/01621459.1981.10477633 · Cited by 1,007
Stringhini, S., Wisniak, A., Piumatti, G., Azman, A. S., Lauer, S. A., Baysson, H., De Ridder, D., Petrovic, D., Schrempft, S., Marcus, K., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31304-0 · Cited by 990
(2001) · Technometrics · doi:10.1198/tech.2001.s612 · Cited by 989
COVID-19 antibody seroprevalence in santa clara county, california
Bendavid, E., Mulaney, B., Sood, N., Shah, S., Bromley-Dulfano, R., Lai, C., Weissberg, Z., Saavedra-Walker, R., Tedrow, J., Bogan, A., et al. (2021) · International Journal of Epidemiology · doi:10.1093/ije/dyab010 · Cited by 669
Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States, March 23–May 12, 2020
Havers, F. P., Reed, C., Lim, T., Montgomery, J. M., Klena, J. D., Hall, A. J., Fry, A. M., Cannon, D. L., Chiang, C.-F., Gibbons, A., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.4130 · Cited by 647
Liu, W., Liu, L., Kou, G., Zheng, Y., Ding, Y., Ni, W., Wang, Q., Tan, L., Wu, W., Tang, S., et al. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00461-20 · Cited by 630
Baqui, P., Bica, I., Marra, V., Ercole, A., & van der Schaar, M. (2020) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30285-0 · Cited by 629
Availability of Recreational Resources in Minority and Low Socioeconomic Status Areas
Moore, L. V., Diez Roux, A. V., Evenson, K. R., McGinn, A. P., & Brines, S. J. (2008) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2007.09.021 · Cited by 572
CDC COVID-19 Response Team, CDC COVID-19 Response Team, Bialek, S., Bowen, V., Chow, N., Curns, A., Gierke, R., Hall, A., Hughes, M., Pilishvili, T., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6915e4 · Cited by 460
Hsu, C.-Y., Lin, F., Vittinghoff, E., & Shlipak, M. G. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000091586.46532.b4 · Cited by 432
High population densities catalyse the spread of COVID-19
Rocklöv, J., & Sjödin, H. (2020) · Journal of Travel Medicine · doi:10.1093/jtm/taaa038 · Cited by 415
Sood, N., Simon, P., Ebner, P., Eichner, D., Reynolds, J., Bendavid, E., & Bhattacharya, J. (2020) · JAMA · doi:10.1001/jama.2020.8279 · Cited by 406
Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China
Xu, X., Sun, J., Nie, S., Li, H., Kong, Y., Liang, M., Hou, J., Huang, X., Li, D., Ma, T., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0949-6 · Cited by 405
Bower, K. M., Thorpe, R. J., Rohde, C., & Gaskin, D. J. (2014) · Preventive Medicine · doi:10.1016/j.ypmed.2013.10.010 · Cited by 376
Frailty, Dialysis Initiation, and Mortality in End-Stage Renal Disease
Bao, Y., Dalrymple, L., Chertow, G. M., Kaysen, G. A., & Johansen, K. L. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.3020 · Cited by 370
Self-citationSerology testing in the COVID-19 pandemic response
Peeling, R. W., Wedderburn, C. J., Garcia, P. J., Boeras, D., Fongwen, N., Nkengasong, J., Sall, A., Tanuri, A., & Heymann, D. L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30517-x · Cited by 360
Natural History of Asymptomatic SARS-CoV-2 Infection
Sakurai, A., Sasaki, T., Kato, S., Hayashi, M., Tsuzuki, S.-I., Ishihara, T., Iwata, M., Morise, Z., & Doi, Y. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2013020 · Cited by 274
Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York
Rosenberg, E. S., Tesoriero, J. M., Rosenthal, E. M., Chung, R., Barranco, M. A., Styer, L. M., Parker, M. M., John Leung, S.-Y., Morne, J. E., Greene, D., et al. (2020) · Annals of Epidemiology · doi:10.1016/j.annepidem.2020.06.004 · Cited by 262
Holt, D., & Smith, T. M. F. (1979) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344652 · Cited by 257
Alberici, F., Delbarba, E., Manenti, C., Econimo, L., Valerio, F., Pola, A., Maffei, C., Possenti, S., Lucca, B., Cortinovis, R., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.04.030 · Cited by 248
Population density and basic reproductive number of COVID-19 across United States counties
Sy, K. T. L., White, L. F., & Nichols, B. E. (2021) · PLOS ONE · doi:10.1371/journal.pone.0249271 · Cited by 243
Payne, D. C., Smith-Jeffcoat, S. E., Nowak, G., Chukwuma, U., Geibe, J. R., Hawkins, R. J., Johnson, J. A., Thornburg, N. J., Schiffer, J., Weiner, Z., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6923e4 · Cited by 195
Neighborhood Poverty and Racial Differences in ESRD Incidence
Volkova, N., McClellan, W., Klein, M., Flanders, D., Kleinbaum, D., Soucie, J. M., & Presley, R. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006080934 · Cited by 191
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90036-s · Cited by 158
Ward, H., Atchison, C. J., Whitaker, M. D., et al. (2020) · medRxiv · doi:10.1101/2020.08.12.20173690v2 · Cited by 155
Clarke, C., Prendecki, M. F., Dhutia, A., Ali, M. A., Sajjad, H., Shivakumar, O., Lightstone, L., Kelleher, P., Pickering, M. C., Thomas, D., et al. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020060827 · Cited by 145
White/black racial differences in risk of end-stage renal disease and death.
Choi, A. I., Rodriguez, R. A., Bacchetti, P., Bertenthal, D., Hernandez, G. T., & O'Hare, A. M. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.11.021 · Cited by 139
Hung, I. F., Cheng, V. C., Li, X., Tam, A. R., Hung, D. L. L., Chiu, K. H., Yip, C. C., Cai, J., Ho, D. T.-Y., Wong, S., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30364-9 · Cited by 124
Low income, community poverty and risk of end stage renal disease
Crews, D. C., Gutiérrez, O. M., Fedewa, S. A., Luthi, J.-C., Shoham, D. A., Judd, S. E., Powe, N. R., & McClellan, W. M. (2014) · BMC Nephrology · doi:10.1186/1471-2369-15-192 · Cited by 109
Employment among Patients Starting Dialysis in the United States
Erickson, K. F., Zhao, B., Ho, V., & Winkelmayer, W. C. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06470617 · Cited by 81
Schnurra, C., Reiners, N., Biemann, R., Kaiser, T., Trawinski, H., & Jassoy, C. (2020) · Journal of Clinical Virology · doi:10.1016/j.jcv.2020.104544 · Cited by 75
Cowger, T. L., Davis, B. A., Etkins, O. S., Makofane, K., Lawrence, J. A., Bassett, M. T., & Krieger, N. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.16933 · Cited by 54
Post-stratification or a non-response adjustment?
Kolenikov, S. (2016) · Survey Practice · doi:10.29115/sp-2016-0014 · Cited by 50
Clinical Validity of Serum Antibodies to SARS-CoV-2: A Case–Control Study
Caturegli, G., Materi, J. D., Howard, B. M., & Caturegli, P. (2020) · Annals of Internal Medicine · doi:10.7326/m20-2889 · Cited by 50
Assessing the extent of SARS-CoV-2 circulation through serological studies
Koopmans, M., & Haagmans, B. L. (2020) · Nature Medicine · doi:10.1038/s41591-020-1018-x · Cited by 37
Estimating COVID-19 Prevalence in the United States: A Sample Selection Model ApproachPreprint
Benatia, D., Godefroy, R., & Lewis, J. (2020) · SSRN Electronic Journal · doi:10.1101/2020.04.20.20072942 · Cited by 25
Cited by
Levin, A. T., Hanage, W. P., Owusu-Boaitey, N., Cochran, K. B., Walsh, S. P., & Meyerowitz-Katz, G. (2020) · European Journal of Epidemiology · doi:10.1007/s10654-020-00698-1 · Cited by 844
The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States
Moghadas, S. M., Vilches, T. N., Zhang, K., Wells, C. R., Shoukat, A., Singer, B. H., Meyers, L. A., Neuzil, K. M., Langley, J. M., Fitzpatrick, M. C., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab079 · Cited by 678
COVID-19 antibody seroprevalence in santa clara county, california
Bendavid, E., Mulaney, B., Sood, N., Shah, S., Bromley-Dulfano, R., Lai, C., Weissberg, Z., Saavedra-Walker, R., Tedrow, J., Bogan, A., et al. (2021) · International Journal of Epidemiology · doi:10.1093/ije/dyab010 · Cited by 669
SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis
Bayati, A., Kumar, R., Francis, V., & McPherson, P. S. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100306 · Cited by 499
Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis
Grupper, A., Sharon, N., Finn, T., Cohen, R., Israel, M., Agbaria, A., Rechavi, Y., Schwartz, I. F., Schwartz, D., Lellouch, Y., et al. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03500321 · Cited by 318
Metadata
- Authors
- Anand, S., Montez-Rath, M., Han, J., Bozeman, J., Kerschmann, R., Beyer, P., Parsonnet, J., & Chertow, G. M.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 396
- Issue
- 10259
- Pages
- 1335-1344
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W3089010823
- Cited by
- 265
- References
- 44
- FWCI
- 7.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.